Metraipolis › archive › dc_fc5d2d8f7fce

Neoadjuvant Pembrolizumab Associated with Chemotherapy in Early Triple-Negative Breast Cancer Patients: Real-World Data from a French Single-Center Experience — Europe PMC PMID:41681830

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41681830
DOI
10.3390/cancers18030358
License (as archived)
solo-consultazione
Archived
2026-11-06T12:52:36.271Z
SHA-256 of the archived text
ef83994ef1b6e2e949a293a6a4a6c11851b5d144a5be68781afadc4ae152f15c
Stable URL of this page
https://metraipolis.com/documento/dc_fc5d2d8f7fce

How to cite

Neoadjuvant Pembrolizumab Associated with Chemotherapy in Early Triple-Negative Breast Cancer Patients: Real-World Data from a French Single-Center Experience — Europe PMC PMID:41681830 — Europe PMC (en), https://europepmc.org/article/MED/41681830 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_fc5d2d8f7fce (Metraipolis archive dc_fc5d2d8f7fce, sha256 ef83994ef1b6e2e949a293a6a4a6c11851b5d144a5be68781afadc4ae152f15c)
BibTeX
@misc{dcfc5d2d8f7fce,
  title = {Neoadjuvant Pembrolizumab Associated with Chemotherapy in Early Triple-Negative Breast Cancer Patients: Real-World Data from a French Single-Center Experience — Europe PMC PMID:41681830},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41681830},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_fc5d2d8f7fce; sha256 ef83994ef1b6e2e949a293a6a4a6c11851b5d144a5be68781afadc4ae152f15c},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41681830. Agents can read the archived copy with the MCP tool read_document.